Translation of "taux de prise en charge " (French → English) :

in all cases of return, information to third-country nationals on return in general, counselling to individuals on the possibilities for voluntary return, translation costs, procurement of indispensable travel documents, costs of necessary pre-return medical checks, costs of travel and food for returnees and escorts, including medical staff and interpreters, accommodation for escorts including medical staff and interpreters, costs of transport in the Member State and up to the country of return and cooperation with the authorities of the country of origin, former residence or transit.

in all cases of return, information to third-country nationals on return in general, counselling to individuals on the possibilities for voluntary return, translation costs, procurement of indispensable travel documents, costs of necessary pre-return medical checks, costs of travel and food for returnees and escorts, including medical staff and interpreters, accommodation for escorts including medical staff and interpreters, costs of transport in the Member State and up to the country of return and cooperation with the authorities of the country of origin, former residence or transit;

In February 2004, an anti-absorption investigation concerning imports of the sulphanilic acid originating in the PRC was concluded by Council Regulation (EC) No 236/2004 (8), which increased the rate of the definitive anti-dumping duty for the PRC from 21 % to 33,7 % (‘the anti-absorption investigation’).

In 2012, the project RARECARENET (Information Network on Rare Cancers)[46], which built upon some of previous activities of the Project RARECARE (Surveillance of Rare Cancers in Europe)[47] which provided estimations for incidence, survival, prevalence and mortality for all rare cancers. The project aims (i) to provide updated indicators of rare cancer burden, (ii) to collect and disseminate information on the health care pathways for rare cancers, (iii) to identify the criteria for centres of expertise for rare cancers, (iv) to produ ...[+++]ce and disseminate information on diagnosis and management of rare cancers, (v) to develop a clinical database on very rare cancers, (vi) to provide new knowledge on these diseases and their clinical management, and (vii) to develop and disseminate information for patients including a list of patients’ associations dedicated to rare cancers. In 2013, the European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment (ExPO-r-NeT), to support the provision of healthcare to children and young people with cancer in a Member State other than the Member State of affiliation, when the expertise with certain cancer conditions is rare and case volume low, contributing to provide cross-border best care to rare childhood cancer populations.

In 2012, the project RARECARENET (Information Network on Rare Cancers)[46], which built upon some of previous activities of the Project RARECARE (Surveillance of Rare Cancers in Europe)[47] which provided estimations for incidence, survival, prevalence and mortality for all rare cancers. The project aims (i) to provide updated indicators of rare cancer burden, (ii) to collect and disseminate information on the health care pathways for rare cancers, (iii) to identify the criteria for centres of expertise for rare cancers, (iv) to produ ...[+++]ce and disseminate information on diagnosis and management of rare cancers, (v) to develop a clinical database on very rare cancers, (vi) to provide new knowledge on these diseases and their clinical management, and (vii) to develop and disseminate information for patients including a list of patients’ associations dedicated to rare cancers. In 2013, the European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment (ExPO-r-NeT), to support the provision of healthcare to children and young people with cancer in a Member State other than the Member State of affiliation, when the expertise with certain cancer conditions is rare and case volume low, contributing to provide cross-border best care to rare childhood cancer populations.

Whereas, since the invitation to tender covers all the costs of first processing and market preparation and all transport costs from the place where the goods are taken over to the place of storage, the costs of processing should be supplemented by an amount corresponding to current taking-over and transport costs ; whereas this amount can be fixed on the basis of an estimate of the distances to be considered normal between the place where the goods are taken over, the undertaking in question and the place of storage;